

Standard Operating Procedure
Criteria for patients to join Breast Self-Management Pathway (SMP)

Purpose:	Define the criteria to be applied when placing Breast Cancer patients onto the Self-Managed Pathway, and the criteria for excluding them from it.			
Scope:	Clinicians, ANP's, CNS's, MDT Co-ordinator; Macmillan Breast Care Navigator			
SOP Reference Number:	SMP 1			
SOP Relates To:	Personalised Breast Cancer Follow up			
Date of Issue:	15/02/2021			
Date of Review	Above + 24m			
Version Control:	Version	Date	Author(s)	Summary of Changes
	V0.3	22/5/19	Mike Barnett	Ready for directorate review
	V0.4	14/01/2021	Dorinda Palmer	Criteria for SMP updated as agreed by MDT members following annual review

Introduction

The care pathway for breast cancer patients is decided upon at a MDT.

This SOP defines the criteria which are applied when deciding whether patients will join the Self-Managed Pathway (SMP) or continue on a Professional-Led follow up pathway.

Scope

This SOP applies to ALL staff who are involved in each individual patient's pathway.

	Instruction	Rationale / Explanation / References
1.	<p>Newly diagnosed patients The decision of which care pathway they should follow takes place at the Breast MDT meeting, typically held weekly.</p> <p>All patients will join the SMP <u>unless</u> assessed as needing professional care.</p> <p>Patients needing professional care are those with conditions appearing in the exclusion list shown opposite.</p> <p>Inclusion notes for particular patient groups</p> <ul style="list-style-type: none"> • Patients on bisphosphonates or Herceptin can continue to be on SMP alongside their oncology treatment appointments • Trials patients will have trial follow-up alongside SMP 	<p><u>Exclusion list:</u> Patients with these conditions are <u>excluded</u> from the SMP, and will join the Professional Care Pathway:</p> <ul style="list-style-type: none"> • Unable to self-manage (self-examine or recognise alert symptoms) due to physical, cognitive, communication or emotional reasons • Complex co-morbidities due to which standard adjuvant treatment cannot be given • Locally advanced cancer at presentation • Patient has residual disease post neo-adjuvant chemotherapy treatment

Instruction	Rationale / Explanation / References
<ul style="list-style-type: none"> Criteria for male breast cancer follow-up will be the same Patients undergoing oncoplastic procedure will continue SMP follow-up alongside oncoplastic follow-up Patients with local recurrence will be on SMP after completing intense adjuvant treatment if complete response is achieved following oncology review 	
<p>2. The decision of the MDT will be communicated to the patient at a 'Post op Results Clinic', on most occasions this will take place the week after the MDT, clinic capacity committing.</p> <p>The decision of the MDT will be recorded onto the relevant patient file in the Somerset system by the MDT Co-ordinator.</p> <p>The patient will be booked into the Results Clinic on Medway by BCN clerical support/ward clerk/ secretary and advised by standard template letter</p>	
<p>3. Patients attending follow-up appointments can join the SMP, by mutual agreement between the patient and clinician.</p> <p>See SOP – SMP 2</p>	